ERBB2 and breast cancer: Our findings also complement the SEER analysis, which was limited to survival data, and demonstrated excellent (99.6%) 5-year BC-specific survival in >21,000 N0 HR + HER2-negative BC patients with RS < 18.15 Our results are also consistent with those reported for the WSG PlanB analysis where the patient population had overall higher risk of recurrence based on clinicopathological characteristics than in our patient population.12 The PlanB analysis included HR + HER2-negative node-positive or high-risk (T2, grade 2 or 3, high uPA/PAI-1, or <35 years of age) node-negative patients.